Cargando…
Drug-induced aneuploidy and polyploidy is a mechanism of disease relapse in MYC/BCL2-addicted diffuse large B-cell lymphoma
Double-hit (DH) or double-expresser (DE) lymphomas are high-grade diffuse large B-cell lymphomas (DLBCL) that are mostly incurable with standard chemo-immunotherapy due to treatment resistance. The generation of drug-induced aneuploid/polyploid (DIAP) cells is a common effect of anti-DLBCL therapies...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267596/ https://www.ncbi.nlm.nih.gov/pubmed/30542505 http://dx.doi.org/10.18632/oncotarget.26251 |
_version_ | 1783376111105736704 |
---|---|
author | Islam, Shariful Paek, Andrew L. Hammer, Michael Rangarajan, Savithri Ruijtenbeek, Robert Cooke, Laurence Weterings, Eric Mahadevan, Daruka |
author_facet | Islam, Shariful Paek, Andrew L. Hammer, Michael Rangarajan, Savithri Ruijtenbeek, Robert Cooke, Laurence Weterings, Eric Mahadevan, Daruka |
author_sort | Islam, Shariful |
collection | PubMed |
description | Double-hit (DH) or double-expresser (DE) lymphomas are high-grade diffuse large B-cell lymphomas (DLBCL) that are mostly incurable with standard chemo-immunotherapy due to treatment resistance. The generation of drug-induced aneuploid/polyploid (DIAP) cells is a common effect of anti-DLBCL therapies (e.g. vincristine, doxorubicin). DIAP cells are thought to be responsible for treatment resistance, as they are capable of re-entering the cell cycle during off-therapy periods. Previously we have shown that combination of alisertib plus ibrutinib plus rituximab can partially abrogate DIAP cells and induce cell death. Here, we provide evidence that DIAP cells can re-enter the cell cycle and escape cell death during anti-DLBCL treatment. We also discuss MYC/BCL2 mediated molecular mechanism that underlie treatment resistance. We isolated aneuploid/polyploid populations of DH/DE-DLBCL cells after treatment with the aurora kinase (AK) inhibitor alisertib. Time-lapse microscopy of single polyploid cells revealed that following drug removal, a subset of these DIAP cells divide and proliferate by reductive cell divisions, including multipolar mitosis, meiosis-like nuclear fission and budding. Genomic, proteomic, and kinomic profiling demonstrated that alisertib-induced aneuploid/polyploid cells up-regulate DNA damage, DNA replication and immune evasion pathways. In addition, we identified amplified receptor tyrosine kinase and T-cell receptor signaling, as well as MYC-mediated dysregulation of the spindle assembly checkpoints RanGAP1, TPX2 and KPNA2. We infer that these factors contribute to treatment resistance of DIAP cells. These findings provide opportunities to develop novel DH/DE-DLBCL therapies, specifically targeting DIAP cells. KEY POINTS: ● MYC mediated upregulation of TPX2, KPNA2 and RanGAP1 dysregulate the spindle assembly checkpoint in drug-induced polyploid cells. ● Drug-induced polyploid cells re-enter the cell cycle via multipolar mitosis, fission or budding, a mechanism of disease relapse. |
format | Online Article Text |
id | pubmed-6267596 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-62675962018-12-12 Drug-induced aneuploidy and polyploidy is a mechanism of disease relapse in MYC/BCL2-addicted diffuse large B-cell lymphoma Islam, Shariful Paek, Andrew L. Hammer, Michael Rangarajan, Savithri Ruijtenbeek, Robert Cooke, Laurence Weterings, Eric Mahadevan, Daruka Oncotarget Research Paper Double-hit (DH) or double-expresser (DE) lymphomas are high-grade diffuse large B-cell lymphomas (DLBCL) that are mostly incurable with standard chemo-immunotherapy due to treatment resistance. The generation of drug-induced aneuploid/polyploid (DIAP) cells is a common effect of anti-DLBCL therapies (e.g. vincristine, doxorubicin). DIAP cells are thought to be responsible for treatment resistance, as they are capable of re-entering the cell cycle during off-therapy periods. Previously we have shown that combination of alisertib plus ibrutinib plus rituximab can partially abrogate DIAP cells and induce cell death. Here, we provide evidence that DIAP cells can re-enter the cell cycle and escape cell death during anti-DLBCL treatment. We also discuss MYC/BCL2 mediated molecular mechanism that underlie treatment resistance. We isolated aneuploid/polyploid populations of DH/DE-DLBCL cells after treatment with the aurora kinase (AK) inhibitor alisertib. Time-lapse microscopy of single polyploid cells revealed that following drug removal, a subset of these DIAP cells divide and proliferate by reductive cell divisions, including multipolar mitosis, meiosis-like nuclear fission and budding. Genomic, proteomic, and kinomic profiling demonstrated that alisertib-induced aneuploid/polyploid cells up-regulate DNA damage, DNA replication and immune evasion pathways. In addition, we identified amplified receptor tyrosine kinase and T-cell receptor signaling, as well as MYC-mediated dysregulation of the spindle assembly checkpoints RanGAP1, TPX2 and KPNA2. We infer that these factors contribute to treatment resistance of DIAP cells. These findings provide opportunities to develop novel DH/DE-DLBCL therapies, specifically targeting DIAP cells. KEY POINTS: ● MYC mediated upregulation of TPX2, KPNA2 and RanGAP1 dysregulate the spindle assembly checkpoint in drug-induced polyploid cells. ● Drug-induced polyploid cells re-enter the cell cycle via multipolar mitosis, fission or budding, a mechanism of disease relapse. Impact Journals LLC 2018-11-13 /pmc/articles/PMC6267596/ /pubmed/30542505 http://dx.doi.org/10.18632/oncotarget.26251 Text en Copyright: © 2018 Islam et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Islam, Shariful Paek, Andrew L. Hammer, Michael Rangarajan, Savithri Ruijtenbeek, Robert Cooke, Laurence Weterings, Eric Mahadevan, Daruka Drug-induced aneuploidy and polyploidy is a mechanism of disease relapse in MYC/BCL2-addicted diffuse large B-cell lymphoma |
title | Drug-induced aneuploidy and polyploidy is a mechanism of disease relapse in MYC/BCL2-addicted diffuse large B-cell lymphoma |
title_full | Drug-induced aneuploidy and polyploidy is a mechanism of disease relapse in MYC/BCL2-addicted diffuse large B-cell lymphoma |
title_fullStr | Drug-induced aneuploidy and polyploidy is a mechanism of disease relapse in MYC/BCL2-addicted diffuse large B-cell lymphoma |
title_full_unstemmed | Drug-induced aneuploidy and polyploidy is a mechanism of disease relapse in MYC/BCL2-addicted diffuse large B-cell lymphoma |
title_short | Drug-induced aneuploidy and polyploidy is a mechanism of disease relapse in MYC/BCL2-addicted diffuse large B-cell lymphoma |
title_sort | drug-induced aneuploidy and polyploidy is a mechanism of disease relapse in myc/bcl2-addicted diffuse large b-cell lymphoma |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267596/ https://www.ncbi.nlm.nih.gov/pubmed/30542505 http://dx.doi.org/10.18632/oncotarget.26251 |
work_keys_str_mv | AT islamshariful druginducedaneuploidyandpolyploidyisamechanismofdiseaserelapseinmycbcl2addicteddiffuselargebcelllymphoma AT paekandrewl druginducedaneuploidyandpolyploidyisamechanismofdiseaserelapseinmycbcl2addicteddiffuselargebcelllymphoma AT hammermichael druginducedaneuploidyandpolyploidyisamechanismofdiseaserelapseinmycbcl2addicteddiffuselargebcelllymphoma AT rangarajansavithri druginducedaneuploidyandpolyploidyisamechanismofdiseaserelapseinmycbcl2addicteddiffuselargebcelllymphoma AT ruijtenbeekrobert druginducedaneuploidyandpolyploidyisamechanismofdiseaserelapseinmycbcl2addicteddiffuselargebcelllymphoma AT cookelaurence druginducedaneuploidyandpolyploidyisamechanismofdiseaserelapseinmycbcl2addicteddiffuselargebcelllymphoma AT weteringseric druginducedaneuploidyandpolyploidyisamechanismofdiseaserelapseinmycbcl2addicteddiffuselargebcelllymphoma AT mahadevandaruka druginducedaneuploidyandpolyploidyisamechanismofdiseaserelapseinmycbcl2addicteddiffuselargebcelllymphoma |